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ABSTRACT
Amodiaquine (AQ) is a 4-aminoquinoline derivative which
is intrinsically more active than the other 4-
aminoquinoline, chloroquine, against Plasmodium 
falciparum parasites. The pharmacokinetic parameters of 
amodiaquine and its active metabolite following the 
administration of amodiaquine to healthy volunteers under 
fasted conditionS were compared with those when it was 
co-administered with food.
In an open, two-way crossover study, 16 healthy 
volunteers fasted overnight and were randomized to 
receive a single oral administration of 600 mg (3 tablets) 
of amodiaquine in the absence or presence of a 
standardized high-fat breakfast, administered 30 min 
before drug administration. Blood samples were collected 
up to 192 h and amodiaquine and desethyl amodiaquine 
were assayed by a validated HPLC method.
Relative to the fasting state, the administration of a single 
dose of amodiaquine after a high-fat breakfast resulted in 
delayed median Tmax values (20 min for amodiaquine and 
3 h for desethylamodiaquine). The geometric mean ratios 
(GMR) of fed to fasting conditions indicated increased 
Cmax values for amodiaquine (GMR 1.40) (90% CI: 1.12-
1.48) and desethylamodiaquine (GMR 1.48) (90% CI: 1.09-
1.52) and increased AUC0-t values for amodiaquine (GMR 
1.62) (90% CI: 1.42-1.86) and for desethylamodiaquine 
(GMR 1.26) (90% CI: 1.12-1.36). 
Intake of AQ with a high fat meal resulted in a statistically 
significant increase in blood levels of amodiaquine and 
desethylamodiaquine which may affect its safety and 
tolerability. The findings of this study suggest that 
amodiaquine should not be administered with a high-fat 
meal.
Key words: Amodiaquine, Desethylamodiaquine, Food, 
Pharmacokinetics
INTRODUCTION
Food influences the rate and extent of drug absorption 
by a wide variety of mechanisms: for example delayed 
gastric emptying, increased peristalsis favouring 
dissolution of any drug, and alteration of transport 
mechanisms1. Food-drug interactions can be associated 
with alterations in the pharmacokinetic and 
pharmacodynamic profile of various drugs that may have 
clinical implications. The various phases in which food 
may interact with a co- administered drug are: (i) before 
and during gastrointestinal absorption; (ii) during 
distribution; (iii) during metabolism; and (iv) during 
elimination. A number of intrinsic and extrinsic factors 
influence the pharmacokinetics of a drug in both the fasted 
and the fed states. These include anatomical, pathological, 
and physiological factors as well as the physical and 
chemical properties of the drug, formulation, or excipients 
1. However, the influence of food is largely a matter of the 
design of the pharmaceutical formulation. In addition, the 
mechanism of 'food effect' may involve physiological and 
sensory responses to food, such as changes in
gastrointestinal milieu and gastric emptying rate, reflex 
action, and may also involve the site and route (either 
portal or lymphatic) of drug absorption 1. Although there 
is a vast amount of literature, there is still no rational 
scientific basis to predict the effect of food for a particular 
chemical entity or a chemical class of therapeutic agents. A 
mechanistic understanding of the effects of food may serve 
as a key to the pharmacokinetic optimization of patient 
therapy, both in outpatients and hospitalized patients of 
various age groups.
Amodiaquine is a 4-aminoquinoline derivative that has 
been widely used for treatment of malaria over the past 50 
years 2. It is intrinsically more active than the other 4-
aminoquinoline, chloroquine, against Plasmodium
falciparum parasites, which are moderately chloroquine 
resistant. The drug is therefore increasingly being 
considered as a replacement for chloroquine as a first line 
drug in Africa because of widespread chloroquine 
resistance 2.
The loss of chloroquine due to selection and spread of 
drug resistant Plasmodium falciparum parasites has greatly 
impacted malaria control, especially in highly endemic 
areas of Africa. Since chloroquine removal a decade ago, 
the guidelines to treat falciparum malaria suggest 
combination therapies, preferentially with an artemisinin 
derivative. One of the recommended partner drugs is 
amodiaquine, a pro-drug that relies on its active 
metabolite monodesethylamodiaquine, and is still effective 
in areas of Africa, but not in regions of South America 2.
Upon oral administration, amodiaquine is rapidly 
absorbed and extensively metabolized such that very little 
of the parent drug is detected in the plasma. The main 
metabolite of amodiaquine is N-desethylamodiaquine with 
other minor metabolites being 2-hydroxyl 
desethylamodiaquine and N-bis desethylamodiaquine 2. 
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Whereas the formation of desethylamodiaquine is rapid, 
its elimination is very slow with a terminal half-life of over 
100 h. Amodiaquine and desethylamodiaquine both have 
antimalarial activity, but amodiaquine is 3 times more 
active (2). However, since amodiaquine is rapidly cleared 
and the formed desethylamodiaquine attains high plasma 
concentrations for a long time, amodiaquine is considered 
a prodrug, which is bioactivated to desethylamodiaquine. 
It has been demonstrated that food intake 
simultaneous with or just before drug administration can 
affect drug pharmacokinetics. Amodiaquine is likely to be 
taken with food, and modification of the dosing regimen 
may be required in the event of any subsequent significant 
change in the pharmacokinetics. Therefore, we examined 
the effect of food on the pharmacokinetics of amodiaquine 
by administering it after fasting and high-fat meals.
MATERIALS AND METHOD
Chemicals and reagents:
Amodiaquine dihydrochloride and desethylamodiaquine 
dihydrochloride were obtained from Parke-Davis, U.S.A. 
and quinidine from BDH Laboratory Supplies, Poole, 
England. Amodiaquine dihydrochloride tablets (Parke-
Davis, U.S.A.) were purchased from a retail pharmacy in
Nigeria. HPLC grade acetonitrile and methanol, and 
analytical grade diethylether, perchloric acid, sodium 
hydroxide and hydrochloric acid were purchased from 
Sigma (Sigma-Aldrich chemical company, Germany). 
Instruments and Chromatographic conditions:
A Mersham Pharmacia Biotech IP-900 liquid 
chromatography. (U.S.A) (AKTA) fitted with a variable 
UV detector (model P-900) was used for the analysis. The 
stationary phase was a reversed-phase C18 column 
{Eclipse-XDB-C18-3.5 µm (200 x 4.6 mm I.D.)}. The 
solvent system for HPLC consisted of acetonitrile: 0.02 M 
potassium dihydrogen phosphate (10:90). The pH of the 
mobile phase was adjusted to 4.0 with orthophosphoric 
acid.  The mobile phase was pumped through the column 
at a flow rate of 1.0 ml/min. The experiments were 
performed at ambient temperature. The method was a 
slight modification of Gitau et al. (2004) 3.
Whirl mixer (Fissions), precisions pipettes (MLA), 
table centrifuge (Gallenkamp) and digital sonicator 
(Gallenkamp) were used for the extraction procedure.
Analytical Procedure
To 1 mL of plasma placed in a 15-ml screw capped 
extraction tube were added 20 µL of 500 µg/mL quinidine 
solution (internal standard) and 2 ml of acetonitrile before 
mixing for about 15 seconds, followed by mechanical 
tumbling for 15 min. After centrifuging for 10 min at 3000 
g, the liquid phase was transferred to a clean tube, to 
which was added 2 ml of ammonia. The mixture was then 
extracted by mechanical tumbling for 15 min, with 2 x 5 
ml of diethyl ether. After centrifugation and separation, 
the combined organic phases were evaporated to dryness 
and the residue was reconstituted in 100 µL of methanol 
while a 50 µL aliquot was injected onto the HPLC column.  
Calibration curve based on peak area ratio was 
prepared by spiking drug-free plasma with standard 
solutions of amodiaquine and monodesethylamodiaquine 
to give concentration ranges of 2 – 30 ng/mL and 20 –
300 ng/ mL respectively. The samples were taken through 
the extraction procedure described above.
Subjects
Twelve males and four females adult Nigerians aged 
between 30 and 38 years and weighing between 64 and 75 
kg took part in the study.  They were all judged healthy 
by a physician on the basis of medical history, clinical 
examination, biochemical, and hematological screening 
prior to entry into the study. Subjects were excluded from 
participating if they met one of the following criteria: 
pregnancy, breast feeding, and history of hypersensitivity 
reactions to amodiaquine or similar agents (Chloroquine, 
Quinidine, Quinolones), use of any  medications that could 
potentially interact with the study drug, any liver function 
test more than three times the upper limit of normal, or 
evidence by history or physical examination of 
gastrointestinal, psychiatric, cardiovascular or 
neurological disorders. All participants gave written 
informed consent, and approval was obtained from the 
Research Ethics Board and safety Committee of the 
Federal Medical Centre, Abeokuta, Ogun state.
Study design, Drug administration and Sample 
collection 
The study was an open-label, crossover 
pharmacokinetic study. A single oral dose of 600 mg 
amodiaquine dihydrochloride tablets was given to each of 
the sixteen volunteers with and without food in a 
crossover design after an overnight fast. The caloric 
contents of the high-fat meal were 900 kcal, according to 
the recommendations of US Food and Drug 
Administration guidance 4. The food consisted of a 
standard breakfast of rice with some vegetables, egg, meat 
and 300 ml of whole milk. Eight subjects received 
amodiaquine without food, and the other Eight received 
same with food. They were later reversed after a washout 
period of two weeks. Blood samples (5 ml) were 
withdrawn by venipuncture from the forearm of each 
subject prior to and at 0.08, 0.25, 0.5, 1.5, 3, 5, 24, 48 and 
192 hours after drug administration into heparinised 
tubes. They were immediately centrifuged (3000 g at 20o C 
for 10 min) to separate plasma. The plasma aliquots were 
stored at -20 0C until analyzed.
The plasma samples were analyzed for amodiaquine and 
monodesethylamodiaquine to obtain their baseline 
pharmacokinetics and then to evaluate the effect of food on 
the pharmacokinetics of amodiaquine. 
Pharmacokinetic Evaluation
The pharmacokinetic (PK) parameters for amodiaquine 
and monodesethylamodiaquine were calculated with the 
computer program WinNonLin (version 1.5). The data 
were analyzed using noncompartmental analysis. The 
parameters that could be established were as follows: time 
point of maximum observed concentration in plasma 
(Tmax); concentration in plasma corresponding to Tmax 
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(Cmax); terminal half-life (T1/2); area under the plasma 
concentration versus time (C-t) curve (AUCT). The 
terminal half-life was calculated from the terminal 
elimination rate constant: k. This rate constant was
calculated by means of linear regression of the final part of 
the ln C-t curve. The final half-life could be calculated by 
T1/2 = ln (2)/k = 0.693/k. For the calculation of the 
elimination rate constant, we used the three final 
concentrations of the C-t curve (24, 48, and 192 h). The 
AUCT was calculated by the logarithmic trapezoidal rule. 
The volume of distribution (Vd) was not included because 
the actual Vd cannot be calculated correctly because the 
bioavailability is not known.
Statistical evaluation was performed with the 
statistical program SPSS 7.0. Direct comparisons of the 
raw data were performed using the two-tailed paired t test. 
To evaluate a food effect, the data were log transformed 
and evaluated using the Wilcoxon test. 
RESULTS
All subjects could tolerate the dose of 600 mg 
amodiaquine. The most frequently reported adverse event 
was mild nausea (twelve subjects). Mild abdominal pain 
occurred in a further three subjects. There were no serious 
adverse events during the study and no withdrawal due to 
adverse events or for any other reason.The result as 
shown in Table 1 shows that relative to the fasting state, 
the administration of amodiaquine after a high-fat 
breakfast resulted in a delayed median Tmax values for 
amodiaquine (20 min) and for desethylamodiaquine (3 h). 
The geometric mean ratios (GMR) of fed to fasting 
conditions indicated increased Cmax values for 
amodiaquine (GMR 1.40) (90% CI: 1.12-1.48) and 
desethylamodiaquine (GMR 1.48) (90% CI: 1.09-1.52) and 
increased AUCT values for amodiaquine (GMR 1.62) (90% 
CI: 1.42-1.86) and for desethylamodiaquine (GMR 1.26) 
(90% CI: 1.12-1.36). The mean Cmax of amodiaquine was 
significantly higher in the fed regimen than in the fasted 
one (38%, P < 0.05), with a corresponding increase in the 
Cmax of desethylamodiaquine (44%, P < 0.05). There was 
also a significant increase in the AUCT of amodiaquine and 
desethylamodiaquine in the fed regimen (36%, P < 0.05 
and 32%, P < 0.05), respectively.  The mean plasma 
concentration–time profiles of amodiaquine after oral 
administration of amodiaquine 600 mg to 16 healthy 
volunteers under fasting, and high-fat meal conditions, 
respectively, and that for desethylamodiaquine are shown 
in Figure 1.
There were no significant differences between the 
treatment groups regarding adverse events, vital signs, 
and laboratory tests, (data not shown).
Table 1: Effect of food on the pharmacokinetic parameters of amodiaquine and  desethylamodiaquine
Parameters Fasting High-fat meal Significance
Amodiaquine
Cmax (ng/ml) 50.0 ± 1.2 68.2 ± 5.6 P < 0.05
Tmax (h) 0.8 ± 0.08 1.08 ± 0.06 P < 0.05
AUC 160.80 ± 15.22 254.68 ± 22.14 P < 0.05
T1/2 6.21 ± 0.82 5.92 ± 0.74 P > 0.05
Desethylamadiaquine
Cmax (ng/ml) 192 ± 17.24 226 ± 24.28 P < 0.05
Tmax (h) 4.20 ± 0.82 5.53± 0.96 P < 0.05
AUC 2054 ± 86.21 2671± 84.34 P < 0.05
A.
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B.
Figure 1: Plasma concentration – time profile of (A) Amodiaquine and (B) Desethylamodiaquine following administration of 
600 mg amodiaquine to 16 healthy volunteers with or without food.
DISCUSSION AND CONCLUSION:
This study was performed to examine the effect of food on 
the pharmacokinetics of amodiaquine, a 4-aminoquinolone 
antimalarial drug. As a high-fat diet frequently affects 
drug absorption, this study attempted to determine the 
maximum effect of food on the pharmacokinetics of 
amodiaquine by drug administration after a high-fat meal. 
The differences in pharmacokinetics between fed 
conditions and the fasting condition were assessed by 
Tmax, Cmax and AUCT.
Pharmacokinetic interactions of orally administered drugs 
and food components have been extensively reviewed 5,6. 
Food can affect bioavailability of drugs by altering the 
physiology of the gastrointestinal tract and by direct 
influence on the formulation and/or drug itself. Direct 
effects of food on the formulation can result from changes 
in solubility of the active drug ingredient through 
physicochemical interactions. Physiologic changes that 
can influence bioavailability include change in the rate of 
gastric emptying, changes in gastric secretions, and effects 
on active transport of drugs. Dietary constituents also can 
affect the biotransformation of a drug in the gastro-
intestinal lumen, gastrointestinal wall, and liver. Drug 
bioavailability can be increased, decreased, delayed, or 
unchanged by the presence of food. Critical factors that 
determine the outcome of such interactions include the 
nature of the drug and food as well as the timing of food 
consumption. Different food components can have 
different effects, and food may interact in opposite ways 
even with drugs that are chemically related6 .
The co-administration of a high-fat meal with 600 mg 
amodiaquine induced a marked increase in Tmax and 
Cmax for amodiaquine. There was also, on average, an 
increase in the AUC T in the ‘fed’ relative to the ‘fasted’ 
state.
In the study, the absorption rate was found higher after a 
high-fat meal. This might have resulted from the 
lipophilicity of amodiaquine. In general, drugs with a high 
lipophilicity exhibit increased absorption when they are 
administered with a high-fat diet 5, which increases 
pancreatic and biliary secretion, resulting in an increased 
dissolution rate. Amodiaquine is lipophilic, displaying a 
0.80–1.85 octanol/water partition coefficient (Log P) in 
approximately pH 1 to pH 7 7. Thus, it can be inferred that 
the increased solubility by the high-fat meal was 
responsible for the higher absorption rate of amodiaquine 
compared with the fasting state.
Previous reports have shown that amodiaquine is well 
absorbed from the gastrointestinal tract 8. Its elimination 
half-life is approximately 3–4 h and amodiaquine is rapidly 
cleared by extensive metabolism followed by excretion of 
metabolites in the urine. The delayed T max and increase 
C max observed in the ‘fed’ session of the present study are 
probably due to a faster gastric emptying time after food 
intake. The increase in AUCT in the ‘fed’ condition, 
however, suggests that, when amodiaquine is co-
administered with food, its bioavailability is increased. 
Despite our small sample size, we detected the well-known 
amodiaquine-related adverse drug reactions. Clinically 
important adverse events were reported by a quarter of 
these volunteers, even though all were healthy and only 
two doses were administered two weeks apart (rather than 
the daily administration for 3 days recommended for 
malaria treatment).
Intake of amodiaquine with a high fat meal resulted in a 
statistically significant increase in blood levels of 
amodiaquine and desethylamodiaquine which may affect 
the safety and tolerability of the study drug.
      
AJPRHC
Research Article
AJPRHC                      Volume 3                          Issue 4                                          Page 109-113
REFERENCES
1. Parrott, N, Lukacova, G,. Fraczkiewicz G.and M. B. 
Bolger, M. B. (2009). Predicting Pharmacokinetics of 
Drugs Using Physiologically Based Modeling 
Application to Food Effects The AAPS Journal 11: 45-
53
2. Juliana, M. S. and Olivia T. (2010): Protecting the 
malarial drug arsenal: halting the rise and spread of 
amodiaquine resistance by monitoring the PFCRT, 
SVMNT type. Mal. Journ. 9: 374.
3. Gitau, E. N.,Muchohi, S. N.,Ogutu, B. R., Githiga, 
L.M., and Kokwaro, G. O. (2004). Selective and sensitive 
liquid chromatographic assay of amodiaquine and 
desethylamodiaquine in whole blood spotted on filter 
paper. J. chrom. B 799: 173-177.
4. US Department of Health and Human Services, Food 
and Drug Administration, Center for Drug Evaluation 
and Research. Guidance for Industry: Food-Effect 
Bioavailability and Fed Bioequivalence Studies. Rockville, 
MD: US Department of Health and Human Services, 
Food and Drug Administration, Center for Drug 
Evaluation and Research; 2002. 
5. Singh BN.  (1999). Effects of food on clinical 
pharmacokinetics. Clin Pharmacokinet. 37:213–55. 
6. Krishna, R., Bradford, K., Jensen, B. (1999). 
Pharmacokinetics: Effects of Food and Fasting. Clin 
Pharmacokinet. 37(3):213-55.
7.Hayeshi R, Masimirembwa, C, Mukanganyama, S., 
Ungell, B. (2008) Lysosomal trapping of amodiaquine: 
impact on transport across intestinal epithelia models. 
Biopharmaceutics & Drug Disposition. 29: 324–334.
8.Fitoussi S, Thang C, Lesauvage E, Barré J, Charron B, 
Filali-Ansary A, Lameyre V. (2009). Bioavailability of a 
co-formulated combination of amodiaquine and 
artesunate under fed and fasted conditions. A 
randomised, open-label crossover study. 
Arzneimittelforschung, 59(7):370-6.
AUTHORS AFFILIATIONS 
AND ADDRESS FOR CORRESPONDENCE
  Dr. J. O. Soyinka
Department of Pharmaceutical Chemistry
Faculty of Pharmacy
Obafemi Awolowo University,
Ile-Ife, Nigeria
Tel: +234 8035822785
Email: juliussoyinka@gmail.com. 
Abeokuta, Nigeria. 
